Brain metastasis from renal cell carcinoma
- 31 July 2008
- Vol. 113 (7), 1641-1648
- https://doi.org/10.1002/cncr.23769
Abstract
BACKGROUND. Patients with renal cell carcinoma brain metastases (RCCBM) are frequently excluded from trials and to the authors' knowledge no guidelines currently exist regarding central nervous system (CNS) surveillance or treatment. The objective of the current study was to assist in the creation of treatment guidelines. METHODS. Patients undergoing evaluation for RCCBM from 1989 to 2006 were identified. Their characteristics, symptoms, pathologic variables, number and size of RCCBM, CNS treatment, CNS recurrence, overall survival, and use of systemic therapy were reviewed. RESULTS. A total of 138 patients were identified with RCCBM, of whom 92% had clear cell RCC and 95% had synchronous extracranial metastases. CNS symptoms were noted in 67% of patients. Symptomatic CNS tumors were larger (2.1 cm vs 1.3 cm; P < .001) and more frequently required a craniotomy (P < .001). The median overall survival after a diagnosis of RCCBM was 10.7 months; the 1‐year, 2‐year, and 5‐year survival rates were 48%, 30%, and 12%, respectively. Median CNS recurrence was 9 months after RCCBM treatment. The initial number of tumors (>1 tumor) was found to be an independent predictor of CNS recurrence (hazards ratio of 3.72; P < .001). Those patients with 1 and >1 lesion had a median CNS recurrence‐free survival of 13 months and 4 months, respectively (P < .001). Patients receiving interleukin‐2 after CNS treatment had a response rate of 17%. CONCLUSIONS. Patients with metastatic RCC should undergo CNS screening to allow the identification of smaller lesions that are more amenable to treatment. Those patients with solitary RCCBM are less likely to develop CNS recurrence after local therapy. Selected patients with good performance status may exhibit prolonged survival and should be offered aggressive therapy. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 22 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- POSTOPERATIVE SURVEILLANCE PROTOCOL FOR PATIENTS WITH LOCALIZED AND LOCALLY ADVANCED RENAL CELL CARCINOMA BASED ON A VALIDATED PROGNOSTIC NOMOGRAM AND RISK GROUP STRATIFICATION SYSTEMJournal of Urology, 2005
- Stereotactic Radiosurgery without Radiation Therapy Providing High Local Tumor Control of Multiple Brain Metastases from Renal Cell Carcinomamin - Minimally Invasive Neurosurgery, 2004
- Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor controlJournal of Neurosurgery, 2003
- Follow‐up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomyBJU International, 1999
- STAGE SPECIFIC GUIDELINES FOR SURVEILLANCE AFTER RADICAL NEPHRECTOMY FOR LOCAL RENAL CELL CARCINOMAJournal of Urology, 1998
- Surgical resection of brain metastases from renal cell carcinoma in 50 patientsUrology, 1996
- A New Protocol for the Followup of Renal Cell Carcinoma Based on Pathological StageJournal of Urology, 1995
- High incidence of asymptomatic brain lesions in metastatic renal cell carcinomaJournal of Neuro-Oncology, 1995
- Cerebral neoplasms initially presenting with massive intracerebral hemorrhageSurgical Neurology, 1984